289 related articles for article (PubMed ID: 38804384)
1. Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses.
Kutikuppala LVS; Kourampi I; Kanagala RSD; Bhattacharjee P; Boppana SH
Med Sci (Basel); 2024 May; 12(2):. PubMed ID: 38804384
[TBL] [Abstract][Full Text] [Related]
2. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
3. A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
Laczkó D; Hogan MJ; Toulmin SA; Hicks P; Lederer K; Gaudette BT; Castaño D; Amanat F; Muramatsu H; Oguin TH; Ojha A; Zhang L; Mu Z; Parks R; Manzoni TB; Roper B; Strohmeier S; Tombácz I; Arwood L; Nachbagauer R; Karikó K; Greenhouse J; Pessaint L; Porto M; Putman-Taylor T; Strasbaugh A; Campbell TA; Lin PJC; Tam YK; Sempowski GD; Farzan M; Choe H; Saunders KO; Haynes BF; Andersen H; Eisenlohr LC; Weissman D; Krammer F; Bates P; Allman D; Locci M; Pardi N
Immunity; 2020 Oct; 53(4):724-732.e7. PubMed ID: 32783919
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 Vaccine: A comprehensive status report.
Kaur SP; Gupta V
Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
[TBL] [Abstract][Full Text] [Related]
5. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccines: Knowing the unknown.
Lv H; Wu NC; Mok CKP
Eur J Immunol; 2020 Jul; 50(7):939-943. PubMed ID: 32437587
[TBL] [Abstract][Full Text] [Related]
7. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.
Shih HI; Wu CJ; Tu YF; Chi CY
Biomed J; 2020 Aug; 43(4):341-354. PubMed ID: 32532623
[TBL] [Abstract][Full Text] [Related]
8. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.
Wang F; Kream RM; Stefano GB
Med Sci Monit; 2020 May; 26():e924700. PubMed ID: 32366816
[TBL] [Abstract][Full Text] [Related]
9. Vaccines for COVID-19: The current state of play.
Koirala A; Joo YJ; Khatami A; Chiu C; Britton PN
Paediatr Respir Rev; 2020 Sep; 35():43-49. PubMed ID: 32653463
[TBL] [Abstract][Full Text] [Related]
10. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA
Adv Drug Deliv Rev; 2021 Mar; 170():113-141. PubMed ID: 33422546
[TBL] [Abstract][Full Text] [Related]
11. Review: N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?
Rubio-Casillas A; Cowley D; Raszek M; Uversky VN; Redwan EM
Int J Biol Macromol; 2024 May; 267(Pt 1):131427. PubMed ID: 38583833
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
13. From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.
Chakraborty C; Sharma AR; Bhattacharya M; Lee SS
Front Immunol; 2021; 12():679344. PubMed ID: 34305909
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.
Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV
Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668
[TBL] [Abstract][Full Text] [Related]
15. Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2.
Tahir Ul Qamar M; Shahid F; Aslam S; Ashfaq UA; Aslam S; Fatima I; Fareed MM; Zohaib A; Chen LL
Infect Dis Poverty; 2020 Sep; 9(1):132. PubMed ID: 32938504
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 vaccine development and a potential nanomaterial path forward.
Shin MD; Shukla S; Chung YH; Beiss V; Chan SK; Ortega-Rivera OA; Wirth DM; Chen A; Sack M; Pokorski JK; Steinmetz NF
Nat Nanotechnol; 2020 Aug; 15(8):646-655. PubMed ID: 32669664
[TBL] [Abstract][Full Text] [Related]
17. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.
Kim KD; Hwang I; Ku KB; Lee S; Kim SJ; Kim C
J Microbiol Biotechnol; 2020 Aug; 30(8):1109-1115. PubMed ID: 32627758
[TBL] [Abstract][Full Text] [Related]
18. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
19. Killed whole-genome reduced-bacteria surface-expressed coronavirus fusion peptide vaccines protect against disease in a porcine model.
Maeda DLNF; Tian D; Yu H; Dar N; Rajasekaran V; Meng S; Mahsoub HM; Sooryanarain H; Wang B; Heffron CL; Hassebroek A; LeRoith T; Meng XJ; Zeichner SL
Proc Natl Acad Sci U S A; 2021 May; 118(18):. PubMed ID: 33858942
[TBL] [Abstract][Full Text] [Related]
20. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
Al-Kassmy J; Pedersen J; Kobinger G
Viruses; 2020 Aug; 12(8):. PubMed ID: 32784685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
